What's in a name?
Delta 8, derived from Industrial Hemp.
All cannabinoids, including regular THC, CBD, and delta-8, interact with receptors in the body’s endocannabinoid system. The endocannabinoid system, or ECS, is made up of a network of receptors designed to respond to our body’s own internal cannabinoids, known as endocannabinoids.
The ECS has two main types of receptors, CB-1 in the central nervous system and CB-2 in the immune system. Regular delta-9 THC has a molecular structure similar to one of our internal endocannabinoids, anandamide. This structure allows delta-9 THC to bind to CB-1 receptors, producing the compound’s well documented psychoactive effects.
Delta-8 creates a weaker bond with CB-1 receptors. The shift in the double bond from the ninth carbon to the eighth carbon modifies the molecule’s structure, making it more difficult to bond to the receptors. The result is a much softer psychoactive effect. Delta-8, like CBD, also inhibits regular THC from binding to the CB-1 receptor, lessening its effects.
In general, consumers of delta-8 THC report the same uplifting feelings they get with regular THC, but with a reduction in the uncomfortable side effects of THC ie. paranoia, anxiety. Like most cannabinoids, delta-8 THC has the ability to interact with both CB-1 and CB-2 receptors in our body’s endocannabinoid system, which may suggest that the compound has therapeutic potential, more in depth research is needed.